This space contains information on medical devices, the use of which is reserved for healthcare professionals. In application of the law of December 29, 2011 relating to the strengthening of health security, I certify that I am a health professional and therefore be authorized to access this information.
I am a healthcare professional
Close window if you are not a healthcare professional
Application
Quantification of Bevacizumab
Specific labelling
Arginine: 13C6,15N4>99%
Lysine: 13C6,15N2, >99%
Description
Labelled Bevacuzimab is a full length, recombinant, stable isotope labelled IgG1 monoclonal antibody designed for use as an internal standard for quantitative analysis of Bevacuzimab in plasma samples. Bevacuzimab inhibits the biologic activity of human vascular endothelial growth factor (VEGF) and is used to treat a range of cancers.
This product is for research use only and is not intended for diagnostic or therapeutic use.
For any quantities, please contact us
Custom clearance and freight insurance costs to be borne by the customer.
This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only. Information about licenses for other uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.
